These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33211395)

  • 21. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 22. Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.
    Chen R; Shi Y; Fang N; Shao C; Huang H; Pan R; Xu Y; Wang M; Liu X; Xu K; Zhu R; Wang M
    Cancer Immunol Immunother; 2024 Sep; 73(11):235. PubMed ID: 39271538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic immune checkpoint inhibitor pneumonitis.
    Naidoo J; Cottrell TR; Lipson EJ; Forde PM; Illei PB; Yarmus LB; Voong KR; Feller-Kopman D; Lee H; Riemer J; Wang D; Taube JM; Brahmer JR; Lin CT; Danoff SK; D'Alessio FR; Suresh K
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
    Reuss JE; Suresh K; Naidoo J
    Curr Oncol Rep; 2020 May; 22(6):56. PubMed ID: 32415399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study.
    Lin X; Deng H; Chu T; Chen L; Yang Y; Qiu G; Xie X; Qin Y; Liu M; Xie Z; Ouyang M; Li S; Song Y; Petrella F; Jakopovic M; Tsoukalas N; Solli P; Goto T; Saito Y; Zhou C
    Transl Lung Cancer Res; 2022 Nov; 11(11):2289-2305. PubMed ID: 36519018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
    Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
    J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors.
    Zhang C; Gao F; Jin S; Gao W; Chen S; Guo R
    Ann Palliat Med; 2020 Nov; 9(6):3957-3965. PubMed ID: 33302658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
    Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
    Front Immunol; 2021; 12():818492. PubMed ID: 35095920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
    Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
    BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
    Wang X; Zhao J; Mei T; Liu W; Chen X; Wang J; Jiang R; Ye Z; Huang D
    BMC Cancer; 2024 Feb; 24(1):269. PubMed ID: 38408928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer.
    Tan P; Huang W; He X; Lv F; Cui Y; Du S
    J Immunother; 2023 Feb-Mar 01; 46(2):64-73. PubMed ID: 36637978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
    Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
    BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
    Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
    Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.
    Frost N; Unger K; Blum TG; Misch D; Kurz S; Lüders H; Olive E; Raspe M; Hilbrandt M; Koch M; Böhmer D; Senger C; Witzenrath M; Grohé C; Bauer T; Modest DP; Kollmeier J
    Lung Cancer; 2023 May; 179():107184. PubMed ID: 37040677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management.
    Lin MX; Zang D; Liu CG; Han X; Chen J
    Front Immunol; 2024; 15():1266850. PubMed ID: 38426102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
    Fujiwara Y; Horita N; Namkoong H; Galsky MD
    Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning.
    Cheng J; Pan Y; Huang W; Huang K; Cui Y; Hong W; Wang L; Ni D; Tan P
    Med Phys; 2022 Mar; 49(3):1547-1558. PubMed ID: 35026041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis.
    Zhou C; Yang Y; Lin X; Fang N; Chen L; Jiang J; Deng H; Deng Y; Wan M; Qiu G; Sun N; Wu D; Long X; Zhong C; Xie X; Xie Z; Liu M; Ouyang M; Qin Y; Petrella F; Fiorelli A; Bravaccini S; Kataoka Y; Watanabe S; Goto T; Solli P; Igai H; Saito Y; Tsoukalas N; Nakada T; Li S; Chen R
    Front Immunol; 2022; 13():935779. PubMed ID: 35967342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.
    Beattie J; Rizvi H; Fuentes P; Luo J; Schoenfeld A; Lin IH; Postow M; Callahan M; Voss MH; Shah NJ; Betof Warner A; Chawla M; Hellmann MD
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33568350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.